BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 28743112)

  • 1. MicroRNA-302b-3p Suppresses Cell Proliferation Through AKT Pathway by Targeting IGF-1R in Human Gastric Cancer.
    Guo B; Zhao Z; Wang Z; Li Q; Wang X; Wang W; Song T; Huang C
    Cell Physiol Biochem; 2017; 42(4):1701-1711. PubMed ID: 28743112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
    Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
    Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-302b regulates cell cycles by targeting CDK2 via ERK signaling pathway in gastric cancer.
    Liu FY; Wang LP; Wang Q; Han P; Zhuang WP; Li MJ; Yuan H
    Cancer Med; 2016 Sep; 5(9):2302-13. PubMed ID: 27465546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CREBRF promotes the proliferation of human gastric cancer cells via the AKT signaling pathway.
    Han J; Zhang L; Zhang J; Jiang Q; Tong D; Wang X; Gao X; Zhao L; Huang C
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):40-45. PubMed ID: 29729692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of microRNA‑33a promotes cyclin‑dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation.
    Wang Y; Zhou X; Shan B; Han J; Wang F; Fan X; Lv Y; Chang L; Liu W
    Mol Med Rep; 2015 Nov; 12(5):6491-500. PubMed ID: 26352175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop.
    Deng M; Zeng C; Lu X; He X; Zhang R; Qiu Q; Zheng G; Jia X; Liu H; He Z
    Cancer Lett; 2017 Sep; 403():175-185. PubMed ID: 28634044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-206: Effective Inhibition of Gastric Cancer Progression through the c-Met Pathway.
    Zheng Z; Yan D; Chen X; Huang H; Chen K; Li G; Zhou L; Zheng D; Tu L; Dong XD
    PLoS One; 2015; 10(7):e0128751. PubMed ID: 26186594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
    Xia B; Yang S; Liu T; Lou G
    Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibitory effects of three miR-129 family members on gastric cancer.
    Yu X; Song H; Xia T; Han S; Xiao B; Luo L; Xi Y; Guo J
    Gene; 2013 Dec; 532(1):87-93. PubMed ID: 24055727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer.
    Li J; Ying Y; Xie H; Jin K; Yan H; Wang S; Xu M; Xu X; Wang X; Yang K; Zheng X; Xie L
    FASEB J; 2019 Jan; 33(1):1374-1388. PubMed ID: 30138038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R.
    Wen XP; Ma HL; Zhao LY; Zhang W; Dang CX
    Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):78-85. PubMed ID: 26025408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2.
    Wang L; Yao J; Zhang X; Guo B; Le X; Cubberly M; Li Z; Nan K; Song T; Huang C
    Mol Cancer Res; 2014 Feb; 12(2):190-202. PubMed ID: 24337067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
    J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells.
    Li H; Xu L; Li C; Zhao L; Ma Y; Zheng H; Li Z; Zhang Y; Wang R; Liu Y; Qu X
    Mol Cancer; 2014 Jun; 13():136. PubMed ID: 24885194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-193a-5p and -3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by Targeting ETS1 and CCND1.
    Chou NH; Lo YH; Wang KC; Kang CH; Tsai CY; Tsai KW
    Anticancer Res; 2018 Jun; 38(6):3309-3318. PubMed ID: 29848678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn.
    Ninio-Many L; Grossman H; Shomron N; Chuderland D; Shalgi R
    J Cell Sci; 2013 Jul; 126(Pt 13):2867-76. PubMed ID: 23606749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a.
    Guo B; Liu L; Yao J; Ma R; Chang D; Li Z; Song T; Huang C
    Mol Cancer Res; 2014 Mar; 12(3):313-21. PubMed ID: 24375644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R.
    Zhang Y; Chen X; Lian H; Liu J; Zhou B; Han S; Peng B; Yin J; Liu W; He X
    Oncol Rep; 2014 Mar; 31(3):1445-52. PubMed ID: 24378652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-7 directly targets insulin-like growth factor 1 receptor to inhibit cellular growth and glucose metabolism in gliomas.
    Wang B; Sun F; Dong N; Sun Z; Diao Y; Zheng C; Sun J; Yang Y; Jiang D
    Diagn Pathol; 2014 Nov; 9():211. PubMed ID: 25394492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.